When Yan Valle was just six years old, he scraped his knee when he was playing soccer. It could happen to any young boy. But soon he saw a white patch emerge on his knee. Fast forward nine years, he had some new nicks and bruises from martial arts and shaving. The result: more depigmented….
Mr. Mahaffey is the President and CEO of Clarify Medical, and has over 30 years of pharmaceutical and biotechnology industry experience. In March 2011 he was named President and CEO of Lithera, Inc., later renamed Neothetics, a clinical stage special pharmaceutical aesthetics company. While there he successfully completed an IPO in November 2014. He previously served as CEO of Peplin, Inc. after the dermatology company was acquired by LEO Pharma A/S in 2009, where he played an instrumental role in the transaction. Prior to the acquisition, he served as Peplin’s Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for Cotherix, Inc. where he led the corporate commercialization and successful launch of Ventavis® (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. in 2007. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson in 2003) where he led the launch of Natrecor® (nesiritide) to treat acutely decompensated congestive heart failure. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey has a Chemical Engineering degree from the University of Delaware and an MBA from the University of South Florida.